Jefferies congratulates Ventyx Biosciences (NASDAQ: VTYX) on the Company’s $1.2 Billion Sale to Eli Lilly (NYSE: LLY). We are honored to be serving as Lead Financial Advisor to Ventyx on this transaction. Acquisition of Ventyx and their portfolio of small molecule NLRP3 inhibitors builds on Lilly’s established capabilities in inflammatory-mediated diseases. Jefferies has now advised on five billion-dollar-plus biopharma M&A transactions in the last year, including four of the top ten by value, reinforcing our leadership in the sector and underscoring Jefferies’ role as a trusted, long-term partner of choice for mission-critical, transformative strategic transactions in biopharma.
Jefferies’ Post
More from this author
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development
Congrats Phil and team!!